Legal & General Group PLC Cytokinetics Inc Transaction History

Legal & General Group PLC

  • $368 Billion
  • Q4 2024

A detailed history of Legal & General Group PLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Legal & General Group PLC holds 178,632 shares of CYTK stock, worth $7.72 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
178,632
Previous 180,800 1.2%
Holding current value
$7.72 Million
Previous $9.55 Million 11.98%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025
SELL
$46.36 - $58.62 $100,508 - $127,088
-2,168 Reduced 1.2%
178,632 $8.4 Million
Q3 2024

Feb 28, 2025
SELL
$51.22 - $60.16 $443,309 - $520,684
-8,655 Reduced 4.85%
169,977 $8.97 Million
Q3 2024

Nov 14, 2024
BUY
$51.22 - $60.16 $609,518 - $715,904
11,900 Added 7.05%
180,800 $9.55 Million
Q2 2024

Aug 14, 2024
BUY
$47.86 - $75.05 $1.23 Million - $1.93 Million
25,774 Added 18.01%
168,900 $9.15 Million
Q1 2024

May 14, 2024
SELL
$63.75 - $108.06 $7.86 Million - $13.3 Million
-123,361 Reduced 46.29%
143,126 $10 Million
Q4 2023

Feb 15, 2024
SELL
$26.88 - $83.49 $18,520 - $57,524
-689 Reduced 0.26%
266,487 $22.2 Million
Q3 2023

Nov 14, 2023
SELL
$29.46 - $36.61 $40,065 - $49,789
-1,360 Reduced 0.51%
267,176 $7.87 Million
Q2 2023

Aug 14, 2023
BUY
$32.62 - $40.75 $978 - $1,222
30 Added 0.01%
268,536 $8.76 Million
Q1 2023

May 15, 2023
BUY
$33.36 - $45.71 $63,617 - $87,168
1,907 Added 0.72%
268,506 $9.45 Million
Q4 2022

Feb 14, 2023
BUY
$35.77 - $51.11 $253,573 - $362,318
7,089 Added 2.73%
266,599 $12.2 Million
Q3 2022

Nov 14, 2022
BUY
$38.54 - $54.52 $624,733 - $883,769
16,210 Added 6.66%
259,510 $12.6 Million
Q2 2022

Aug 22, 2022
BUY
$33.93 - $48.92 $133,853 - $192,989
3,945 Added 1.65%
243,300 $9.56 Million
Q1 2022

May 16, 2022
BUY
$29.74 - $46.0 $1.06 Million - $1.65 Million
35,768 Added 17.57%
239,355 $8.81 Million
Q4 2021

Feb 14, 2022
BUY
$34.35 - $46.38 $313,890 - $423,820
9,138 Added 4.7%
203,587 $9.28 Million
Q3 2021

Nov 15, 2021
BUY
$18.54 - $35.74 $715,440 - $1.38 Million
38,589 Added 24.76%
194,449 $6.95 Million
Q2 2021

Aug 12, 2021
SELL
$19.79 - $26.99 $911,646 - $1.24 Million
-46,066 Reduced 22.81%
155,860 $3.08 Million
Q1 2021

May 17, 2021
BUY
$18.57 - $25.68 $26,517 - $36,671
1,428 Added 0.71%
201,926 $4.7 Million
Q4 2020

Feb 12, 2021
BUY
$15.26 - $28.61 $11,506 - $21,571
754 Added 0.38%
200,498 $4.17 Million
Q3 2020

Nov 13, 2020
BUY
$20.58 - $28.96 $648,043 - $911,921
31,489 Added 18.72%
199,744 $4.32 Million
Q2 2020

Aug 14, 2020
BUY
$11.15 - $24.64 $210,701 - $465,622
18,897 Added 12.65%
168,255 $3.97 Million
Q1 2020

May 14, 2020
BUY
$8.75 - $16.3 $7,708 - $14,360
881 Added 0.59%
149,358 $1.76 Million
Q4 2019

Feb 13, 2020
BUY
$7.95 - $11.84 $92,196 - $137,308
11,597 Added 8.47%
148,477 $1.58 Million
Q3 2019

Nov 13, 2019
BUY
$10.82 - $14.25 $18,274 - $24,068
1,689 Added 1.25%
136,880 $1.56 Million
Q2 2019

Aug 14, 2019
BUY
$7.95 - $11.25 $62,948 - $89,077
7,918 Added 6.22%
135,191 $1.52 Million
Q1 2019

May 15, 2019
BUY
$5.95 - $10.19 $75,142 - $128,689
12,629 Added 11.02%
127,273 $1.03 Million
Q4 2018

Feb 15, 2019
SELL
$5.91 - $9.29 $2,003 - $3,149
-339 Reduced 0.29%
114,644 $716,000
Q3 2018

Nov 20, 2018
BUY
$6.4 - $9.85 $102,739 - $158,122
16,053 Added 16.23%
114,983 $1.13 Million
Q2 2018

Aug 10, 2018
BUY
$6.9 - $9.9 $38,812 - $55,687
5,625 Added 6.03%
98,930 $818,000
Q1 2018

May 17, 2018
BUY
$7.2 - $10.05 $24,069 - $33,597
3,343 Added 3.72%
93,305 $674,000
Q4 2017

Feb 13, 2018
BUY
$7.25 - $15.65 $652,224 - $1.41 Million
89,962
89,962 $734,000

Others Institutions Holding CYTK

# of Institutions
396
Shares Held
114M
Call Options Held
3.46M
Put Options Held
1.86M
View Full List

About CYTOKINETICS INC

CYTK Quotes by TradingView
  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $4.07B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email